Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSIONS:
Telmisartan was effective in reducing blood pressure and improving lipid metabolism and renal function. Reduction of endothelin-1 might be related to an endothelial protective effect. On the basis of these findings, and because of properties unrelated to blood pressure lowering, telmisartan might be the first choice antihypertensive drug for the treatment of HIV-positive patients.
|
Authors | Jacopo Vecchiet, Claudio Ucciferri, Katia Falasca, Paola Mancino, Angelo Di Iorio, Raffaele De Caterina |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 16
Issue 5
Pg. 639-45
( 2011)
ISSN: 2040-2058 [Electronic] England |
PMID | 21817185
(Publication Type: Journal Article)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Antihypertensive Agents
- Benzimidazoles
- Benzoates
- Cystatin C
- Endothelin-1
- Interleukin-18
- Lipoproteins, HDL
- Lipoproteins, LDL
- PPAR gamma
- Triglycerides
- Telmisartan
|
Topics |
- Adult
- Angiotensin II Type 1 Receptor Blockers
(metabolism, pharmacology)
- Antihypertensive Agents
(metabolism, pharmacology)
- Benzimidazoles
(metabolism, pharmacology)
- Benzoates
(metabolism, pharmacology)
- Blood Pressure
(drug effects)
- Cardiovascular Diseases
(drug therapy, prevention & control)
- Cystatin C
(blood, drug effects)
- Endothelin-1
(blood, drug effects)
- HIV Seropositivity
(complications, metabolism)
- Humans
- Hypertension
(complications, drug therapy, metabolism, physiopathology)
- Insulin Resistance
- Interleukin-18
(blood, metabolism)
- Lipoproteins, HDL
(blood, drug effects)
- Lipoproteins, LDL
(blood, drug effects)
- Male
- Middle Aged
- PPAR gamma
(agonists, drug effects)
- Risk Factors
- Telmisartan
- Triglycerides
(blood, metabolism)
|